Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity

Innate Pharma SA's IPHA data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low discontinuation rate.

  • Cohort 3 is exploring the triplet combination of monalizumab, cetuximab, and durvalumab in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell cancer.
  • The data will be presented at the ESMO Immuno-Oncology Congress 2021.
  • Monalizumab, Innate's lead partnered asset, is an immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.
  • As of August 1, 40 patients were enrolled. Thirteen patients had a confirmed response with a 32.5% overall response rate, including three complete responses. 
  • Seven out of 13 responders were still on treatment. The median duration of response was not yet reached. 
  • The survival rate at 12 months was 58.6%, and the median overall survival was 15 months.
  • AstraZeneca Plc AZN obtained full oncology rights to monalizumab in October 2018 through a co-development and commercialization agreement initiated in 2015. 
  • Also Read: What Is Happening With Innate Pharma Stock On Friday?
  • Price Action: IPHA shares are up 0.20% at $4.99 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefsneck cancerPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!